Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04230226 · ClinicalTrials.gov registry record · NA

Acute Study on Muscle Soreness, Damage, and Performance

A NA study, sponsored by Pharmanex.

Completed
Registry status
NA
Development phase
32
Enrollment target

NCT04230226: Completed NA study, sponsored by Pharmanex.

NCT04230226 is a NA study that has completed, run by Pharmanex. The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04230226, a NA study, has completed, sponsored by Pharmanex.

COMPLETED
Registry status
NA
Development phase
32 participants
Enrollment target

Study Summary

The acute study will evaluate pre- and post-exercise ingestion of a multi-ingredient supplement in a randomized, double-blind, placebo-controlled, crossover design. Participants will complete one enrollment visit, in which they will sign a consent form and complete a health history questionnaire. Participants will complete two interventions, with three visits each (6 visits total), in which a treatment beverage (pre/post supplement, or non-caloric placebo) will be consumed within 30 minutes prior to exercise and within 15 minutes post-exercise, in random order. Total time from enrollment to completion will be at least 14 days. Testing visits will be separated by a minimum of 7 days of rest to allow for recovery and washout, based on a half-life of ≤8 hours for all ingredients present in the supplement.

Interventions

  • OTHER Placebo
  • DIETARY_SUPPLEMENT Pre-workout plus and protein recovery plus

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2020-01-21
Est. Completion 2020-09-16
Phase NA

Sponsor

Pharmanex

13 total trials

What the Registry Record Tells You About NCT04230226

The ClinicalTrials.gov registry entry for NCT04230226 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharmanex, which has 13 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT04230226 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04230226 about?

NCT04230226 is a clinical study titled "Acute Study on Muscle Soreness, Damage, and Performance". The acute study will evaluate pre- and post-exercise ingestion of a multi-ingredient supplement in a randomized, double-blind, placebo-controlled, crossover design. Participants will complete one enrollment visit, in which they will sign a consent form and complete a health history questionnaire. Pa...

What is the current status of trial NCT04230226?

This trial is currently completed. It is a NA study. The enrollment target is 32 participants. The study started on 2020-01-21. Estimated completion is 2020-09-16.

What interventions are being tested in trial NCT04230226?

The interventions under investigation include: Placebo (OTHER), Pre-workout plus and protein recovery plus (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT04230226?

This trial is sponsored by Pharmanex, which has 13 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.